HPV-16 variants' impact on uterine cervical cancer response to radiotherapy: A descriptive pilot study.
Identifieur interne : 004502 ( Ncbi/Merge ); précédent : 004501; suivant : 004503HPV-16 variants' impact on uterine cervical cancer response to radiotherapy: A descriptive pilot study.
Auteurs : P. Moreno-Acosta [Colombie] ; A. Vallard [France] ; M. Molano [Australie] ; A. Huertas [Colombie] ; Gamboa [Colombie] ; M. Cotes [Colombie] ; A. Romero-Rojas [Colombie] ; C. Rancoule [France] ; N. Magné [France]Source :
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [ 1769-6658 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Femelle, Humains, Infections à papillomavirus (radiothérapie), Papillomavirus humain de type 16 (), Papillomavirus humain de type 16 (génétique), Projets pilotes, Résultat thérapeutique, Sujet âgé, Tumeurs du col de l'utérus (radiothérapie), Tumeurs du col de l'utérus (virologie), Variation génétique, Études prospectives.
- MESH :
- génétique : Papillomavirus humain de type 16.
- radiothérapie : Infections à papillomavirus, Tumeurs du col de l'utérus.
- virologie : Tumeurs du col de l'utérus.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Papillomavirus humain de type 16, Projets pilotes, Résultat thérapeutique, Sujet âgé, Variation génétique, Études prospectives.
English descriptors
- KwdEn :
- Adult, Aged, Female, Genetic Variation, Human papillomavirus 16 (classification), Human papillomavirus 16 (genetics), Humans, Middle Aged, Papillomavirus Infections (radiotherapy), Pilot Projects, Prospective Studies, Treatment Outcome, Uterine Cervical Neoplasms (radiotherapy), Uterine Cervical Neoplasms (virology).
- MESH :
- classification : Human papillomavirus 16.
- genetics : Human papillomavirus 16.
- radiotherapy : Papillomavirus Infections, Uterine Cervical Neoplasms.
- virology : Uterine Cervical Neoplasms.
- Adult, Aged, Female, Genetic Variation, Humans, Middle Aged, Pilot Projects, Prospective Studies, Treatment Outcome.
Abstract
Although the large impact of Human papilloma virus (HPV) in cervical cancer is established, its place as a therapeutic target is new and according to the growing literature, could be promising. In the present study, radiosensitivity's difference based on HPV-16 variants is assessed.
DOI: 10.1016/j.canrad.2016.09.018
PubMed: 28325620
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E51
- to stream PubMed, to step Curation: 000E48
- to stream PubMed, to step Checkpoint: 000E48
Links to Exploration step
pubmed:28325620Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HPV-16 variants' impact on uterine cervical cancer response to radiotherapy: A descriptive pilot study.</title><author><name sortKey="Moreno Acosta, P" sort="Moreno Acosta, P" uniqKey="Moreno Acosta P" first="P" last="Moreno-Acosta">P. Moreno-Acosta</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Biology Research Group, Research Group in Clinical Molecular and Cellular Radiobiology, National Cancer Institute, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Cancer Biology Research Group, Research Group in Clinical Molecular and Cellular Radiobiology, National Cancer Institute, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Vallard, A" sort="Vallard, A" uniqKey="Vallard A" first="A" last="Vallard">A. Vallard</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez</wicri:regionArea><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion></affiliation></author><author><name sortKey="Molano, M" sort="Molano, M" uniqKey="Molano M" first="M" last="Molano">M. Molano</name><affiliation wicri:level="3"><nlm:affiliation>Microbiology and Infection Diseases, The Royal' Women Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Microbiology and Infection Diseases, The Royal' Women Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Huertas, A" sort="Huertas, A" uniqKey="Huertas A" first="A" last="Huertas">A. Huertas</name><affiliation wicri:level="1"><nlm:affiliation>Pathology Group, National University of Colombia, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Pathology Group, National University of Colombia, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Gamboa, " sort="Gamboa, " uniqKey="Gamboa " first="" last="Gamboa"> Gamboa</name><affiliation wicri:level="1"><nlm:affiliation>Unit Group of Analysis, National Cancer Institute, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Unit Group of Analysis, National Cancer Institute, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Cotes, M" sort="Cotes, M" uniqKey="Cotes M" first="M" last="Cotes">M. Cotes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Cancer Institute, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Department of Radiotherapy, National Cancer Institute, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Romero Rojas, A" sort="Romero Rojas, A" uniqKey="Romero Rojas A" first="A" last="Romero-Rojas">A. Romero-Rojas</name><affiliation wicri:level="1"><nlm:affiliation>Pathology Oncology Group, National Cancer Institute, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Pathology Oncology Group, National Cancer Institute, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Rancoule, C" sort="Rancoule, C" uniqKey="Rancoule C" first="C" last="Rancoule">C. Rancoule</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez</wicri:regionArea><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion></affiliation></author><author><name sortKey="Magne, N" sort="Magne, N" uniqKey="Magne N" first="N" last="Magné">N. Magné</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France. Electronic address: nicolas.magne@icloire.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez</wicri:regionArea><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28325620</idno><idno type="pmid">28325620</idno><idno type="doi">10.1016/j.canrad.2016.09.018</idno><idno type="wicri:Area/PubMed/Corpus">000E51</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E51</idno><idno type="wicri:Area/PubMed/Curation">000E48</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E48</idno><idno type="wicri:Area/PubMed/Checkpoint">000E48</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E48</idno><idno type="wicri:Area/Ncbi/Merge">004502</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">HPV-16 variants' impact on uterine cervical cancer response to radiotherapy: A descriptive pilot study.</title><author><name sortKey="Moreno Acosta, P" sort="Moreno Acosta, P" uniqKey="Moreno Acosta P" first="P" last="Moreno-Acosta">P. Moreno-Acosta</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Biology Research Group, Research Group in Clinical Molecular and Cellular Radiobiology, National Cancer Institute, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Cancer Biology Research Group, Research Group in Clinical Molecular and Cellular Radiobiology, National Cancer Institute, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Vallard, A" sort="Vallard, A" uniqKey="Vallard A" first="A" last="Vallard">A. Vallard</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez</wicri:regionArea><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion></affiliation></author><author><name sortKey="Molano, M" sort="Molano, M" uniqKey="Molano M" first="M" last="Molano">M. Molano</name><affiliation wicri:level="3"><nlm:affiliation>Microbiology and Infection Diseases, The Royal' Women Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Microbiology and Infection Diseases, The Royal' Women Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Huertas, A" sort="Huertas, A" uniqKey="Huertas A" first="A" last="Huertas">A. Huertas</name><affiliation wicri:level="1"><nlm:affiliation>Pathology Group, National University of Colombia, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Pathology Group, National University of Colombia, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Gamboa, " sort="Gamboa, " uniqKey="Gamboa " first="" last="Gamboa"> Gamboa</name><affiliation wicri:level="1"><nlm:affiliation>Unit Group of Analysis, National Cancer Institute, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Unit Group of Analysis, National Cancer Institute, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Cotes, M" sort="Cotes, M" uniqKey="Cotes M" first="M" last="Cotes">M. Cotes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Cancer Institute, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Department of Radiotherapy, National Cancer Institute, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Romero Rojas, A" sort="Romero Rojas, A" uniqKey="Romero Rojas A" first="A" last="Romero-Rojas">A. Romero-Rojas</name><affiliation wicri:level="1"><nlm:affiliation>Pathology Oncology Group, National Cancer Institute, Bogotá, Colombia.</nlm:affiliation><country xml:lang="fr">Colombie</country><wicri:regionArea>Pathology Oncology Group, National Cancer Institute, Bogotá</wicri:regionArea><wicri:noRegion>Bogotá</wicri:noRegion></affiliation></author><author><name sortKey="Rancoule, C" sort="Rancoule, C" uniqKey="Rancoule C" first="C" last="Rancoule">C. Rancoule</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez</wicri:regionArea><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion></affiliation></author><author><name sortKey="Magne, N" sort="Magne, N" uniqKey="Magne N" first="N" last="Magné">N. Magné</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France. Electronic address: nicolas.magne@icloire.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez</wicri:regionArea><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion><wicri:noRegion>42271 Saint-Priest-en-Jarez</wicri:noRegion></affiliation></author></analytic><series><title level="j">Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</title><idno type="eISSN">1769-6658</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Genetic Variation</term><term>Human papillomavirus 16 (classification)</term><term>Human papillomavirus 16 (genetics)</term><term>Humans</term><term>Middle Aged</term><term>Papillomavirus Infections (radiotherapy)</term><term>Pilot Projects</term><term>Prospective Studies</term><term>Treatment Outcome</term><term>Uterine Cervical Neoplasms (radiotherapy)</term><term>Uterine Cervical Neoplasms (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Infections à papillomavirus (radiothérapie)</term><term>Papillomavirus humain de type 16 ()</term><term>Papillomavirus humain de type 16 (génétique)</term><term>Projets pilotes</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Tumeurs du col de l'utérus (radiothérapie)</term><term>Tumeurs du col de l'utérus (virologie)</term><term>Variation génétique</term><term>Études prospectives</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Human papillomavirus 16</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Human papillomavirus 16</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Papillomavirus humain de type 16</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Papillomavirus Infections</term><term>Uterine Cervical Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Infections à papillomavirus</term><term>Tumeurs du col de l'utérus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Tumeurs du col de l'utérus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Uterine Cervical Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Genetic Variation</term><term>Humans</term><term>Middle Aged</term><term>Pilot Projects</term><term>Prospective Studies</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Papillomavirus humain de type 16</term><term>Projets pilotes</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Variation génétique</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the large impact of Human papilloma virus (HPV) in cervical cancer is established, its place as a therapeutic target is new and according to the growing literature, could be promising. In the present study, radiosensitivity's difference based on HPV-16 variants is assessed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28325620</PMID><DateCreated><Year>2017</Year><Month>03</Month><Day>22</Day></DateCreated><DateCompleted><Year>2017</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-6658</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</Title><ISOAbbreviation>Cancer Radiother</ISOAbbreviation></Journal><ArticleTitle>HPV-16 variants' impact on uterine cervical cancer response to radiotherapy: A descriptive pilot study.</ArticleTitle><Pagination><MedlinePgn>104-108</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1278-3218(17)30041-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canrad.2016.09.018</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Although the large impact of Human papilloma virus (HPV) in cervical cancer is established, its place as a therapeutic target is new and according to the growing literature, could be promising. In the present study, radiosensitivity's difference based on HPV-16 variants is assessed.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Variants of Human papilloma virus were identified before the exclusive radiotherapy in patients with cervical cancer. Data were prospectively collected. Fifty-nine patients were screened.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 59 screened patients, 34 (57.6%) were identified to be HPV-16 (+), with 13 European and two non-European variants. Of the 34 patients, 15 experienced exclusive radiotherapy. Among them, eight had complete response (seven with European and one with non-European variants), four with European variant had partial response, three with European variant had tumour persistence and one with non-European variant progressed at 3 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">No radiosensitivity difference was established, probably because of the limited population. Non-European variant aggressiveness might be suggested in accordance with the literature, as it was associated with the only tumour progression. Exclusive radiotherapy provides a unique and "pure" model of radioresistance in cervical cancer and could be the missing link between in vitro studies and state of the art chemoradiotherapy studies that probably feature too many parameters to identify radioresistance causes. The present study was a first step, with the future prospects of building a larger cohort study in order to better understand HPV-induced radioresistance and then to be able to propose new made-to-measure treatments.</AbstractText><CopyrightInformation>Copyright © 2017 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno-Acosta</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cancer Biology Research Group, Research Group in Clinical Molecular and Cellular Radiobiology, National Cancer Institute, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallard</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molano</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology and Infection Diseases, The Royal' Women Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huertas</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathology Group, National University of Colombia, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamboa</LastName><ForeName>Ó</ForeName><Initials>Ó</Initials><AffiliationInfo><Affiliation>Unit Group of Analysis, National Cancer Institute, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotes</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Cancer Institute, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-Rojas</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathology Oncology Group, National Cancer Institute, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rancoule</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magné</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Institut de Cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France. Electronic address: nicolas.magne@icloire.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Cancer Radiother</MedlineTA><NlmUniqueID>9711272</NlmUniqueID><ISSNLinking>1278-3218</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052162" MajorTopicYN="Y">Human papillomavirus 16</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">Cidofovir</Keyword><Keyword MajorTopicYN="N">Col utérin</Keyword><Keyword MajorTopicYN="N">HPV-16</Keyword><Keyword MajorTopicYN="N">HPV-16 variants</Keyword><Keyword MajorTopicYN="N">Radiotherapy</Keyword><Keyword MajorTopicYN="N">Radiothérapie</Keyword><Keyword MajorTopicYN="N">Variants</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>08</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28325620</ArticleId><ArticleId IdType="pii">S1278-3218(17)30041-0</ArticleId><ArticleId IdType="doi">10.1016/j.canrad.2016.09.018</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Colombie</li><li>France</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement></list><tree><country name="Colombie"><noRegion><name sortKey="Moreno Acosta, P" sort="Moreno Acosta, P" uniqKey="Moreno Acosta P" first="P" last="Moreno-Acosta">P. Moreno-Acosta</name></noRegion><name sortKey="Cotes, M" sort="Cotes, M" uniqKey="Cotes M" first="M" last="Cotes">M. Cotes</name><name sortKey="Gamboa, " sort="Gamboa, " uniqKey="Gamboa " first="" last="Gamboa"> Gamboa</name><name sortKey="Huertas, A" sort="Huertas, A" uniqKey="Huertas A" first="A" last="Huertas">A. Huertas</name><name sortKey="Romero Rojas, A" sort="Romero Rojas, A" uniqKey="Romero Rojas A" first="A" last="Romero-Rojas">A. Romero-Rojas</name></country><country name="France"><noRegion><name sortKey="Vallard, A" sort="Vallard, A" uniqKey="Vallard A" first="A" last="Vallard">A. Vallard</name></noRegion><name sortKey="Magne, N" sort="Magne, N" uniqKey="Magne N" first="N" last="Magné">N. Magné</name><name sortKey="Rancoule, C" sort="Rancoule, C" uniqKey="Rancoule C" first="C" last="Rancoule">C. Rancoule</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Molano, M" sort="Molano, M" uniqKey="Molano M" first="M" last="Molano">M. Molano</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004502 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004502 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28325620
|texte= HPV-16 variants' impact on uterine cervical cancer response to radiotherapy: A descriptive pilot study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28325620" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |